The IJTLD
The IJTLD is the leading peer-reviewed journal dedicated to lung health worldwide.
We welcome submissions on basic, translational, clinical, epidemiological and programmatic research relevant to the Union’s mission to find health solutions for these conditions.
Click the arrow to find out more
Public Health Action
Public Health Action aims to disseminate the latest operational research on health systems, public health and disease control.
We have recently expanded the scope of PHA to provide coverage of relevant areas of the UN's Sustainable Development Goals (SDGs).
Click the arrow to find out more
IJTLD Open
Launched in January 2024, IJTLD Open is The Union's new Open Access journal for the latest research on TB and lung diseases including asthma, COVID-19 and COPD.
We welcome submissions on the development of diagnostics and treatments for the prevention, management and control of respiratory diseases.
Click the arrow to find out more
Fast-Track Articles
In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain accepted articles from the IJTLD and PHA and publishing them in full on our website, prior to their publication in the Journals. Read fast-track articles:
Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19
In this recently accepted article for IJTLD, the authors found that RR-TB diagnosis decreased by 21–38% following the start of the pandemic. The results are disturbing and suggest that COVID-19 has had a sustained impact at a time when household transmission of TB/RR-TB might have increased due to ‘shelter at home’. The preprint is free to read.
Asymptomatic COVID-19 – implications for the control of transmission in South Africa
The authors conducted a retrospective analysis to determine the proportion of asymptomatic COVID-19 in the workplace during lockdown in early 2020. Nearly 45% of cases were asymptomatic, which has implications for interventions, such as enforcing quarantine of all close contacts of COVID-19 cases regardless of symptoms.
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
In this recently accepted article for IJTLD, the authors performed a cohort-comparison study to assess Pretomanid in a regimen to treat drug-resistant TB: patients receiving the BPaL regimen had a significantly better 6-month post-treatment outcome than those on the B–L regimen. The preprint is free to read.